This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Athersys Presents New Data Demonstrating Potential Benefits From MultiStem After Spinal Cord Injury

CLEVELAND, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) presented new research results this morning at the Society for Neuroscience annual meeting in New Orleans, demonstrating the potential for MultiStem ®, a novel stem cell therapy being developed by Athersys, to treat spinal cord injury (SCI).

The work conducted by Athersys scientists, in collaboration with scientists from Case Western Reserve University School of Medicine, and with grant support from the Ohio Third Frontier, illustrates the potential benefits of MultiStem therapy for treating SCI. In a preclinical rodent model of SCI, researchers observed that intravenous administration of MultiStem cells one day after injury results in accelerated recovery, significant improvements in locomotor function and fine motor tests, and significant improvement in bladder function.

According to the Christopher & Dana Reeve Foundation, there are currently more than 1,200,000 people in the United States living with spinal cord injury, with a range of 15,000 to more than 50,000 new cases each year. The long-term cost of spinal cord damage is estimated to be from $500,000 to more than $3 million per patient, depending on the severity of the injury. Among other SCI complications, loss of bladder control is considered a major issue by SCI patients.

"Spinal cord injury can be devastating to patients and their families," said Robert Mays, Ph.D., Head of Neuroscience at Athersys. "These results suggest that an off-the-shelf cell therapy, such as MultiStem, administered intravenously shortly after the injury, may have the potential to provide substantial and meaningful benefits to patients."

In preclinical experiments, rodents with SCI from contusion in the thoracic region were given an intravenous injection of vehicle or MultiStem cells one day after the injury. The animals treated with MultiStem showed significant and sustained improvement in gross locomotor and fine motor function compared to vehicle treated animals over the ten week evaluation period. Additionally, significant improvements in bladder function were observed in the animals treated with MultiStem shortly after the SCI. These results build on previous data, published in 2011 in the Journal of Neuroscience, demonstrating that this cell therapy reduces inflammation in the region of injury and also promotes the regrowth of neurons in the site of injury.

Jerry Silver, PhD, the lead academic investigator on the project and a Professor in the Department of Neurosciences at Case Western Reserve School of Medicine, commented on the potential for intravenous administration of MultiStem to benefit SCI patients. "I am excited by this non-invasive, acute-treatment approach which represents a novel treatment strategy with the potential to safely and more effectively treat acute spinal cord injury and its related complications."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 0.00%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $241.80 0.00%
YHOO $36.53 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs